COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
[Website not responding at inquiry; receiving 403=Forbidden message]]

 

CanSinoBIO
News
[Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases
August 13, 2021
Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
AMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 13, 2021– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use authorization for the Moderna COVID-19 vaccine (mRNA-1273) to include a third dose for immunocompromised individuals 18 years of age or older in the United States who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise…

August 12, 2021
Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months

August 10, 2021
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

August 9, 2021
Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine

 

Novavax
Press Releases – No new digest announcements identified

 

Pfizer
Recent Press Releases
08.13.2021
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No corporate announcements identified
[Last media release still posted is dated February 15, 2021; media release of April 21, 2021 apparently removed]

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
2021/08/10’
:: CoronaVac® generates good immune memory after second dose
:: Third dose of vaccine significantly increased neutralizing antibody levels in adults and elderly population
:: Findings indicate a third dose of CoronaVac® is well-tolerated in the elderly population
:: No serious vaccine-related adverse reactions reported
BEIJING–SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of two papers, which are available on Medrxiv. The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac® in two- and three-dose schedules. The results indicate that a third booster dose of CoronaVac® induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine. This research provides important scientific data and supplement existing research to help policymakers develop strategies for vaccine rollout and timing of booster doses…

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

 

SK Biosciences
Press releases
SK bioscience’s COVID-19 Vaccine will enter Phase III clinical trial with Promising Interim Data
2021. 08. 10
:: Phase I/II stage 1 confirms 5~8 folds of neutralizing antibody titer compared to human convalescent sera
:: Acceptable safety profile… concurrently developing vaccine candidates against virus variants
:: Global collaboration enables move to Phase III clinical trial … potential for worldwide equitable vaccine access upon completion of vaccine development